MS drug use in pregnancy under the microscope: is it safe for baby?
NCT ID NCT06053749
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study looks at how many women with multiple sclerosis (MS) use the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to know if there are enough cases to study whether the drug affects pregnancy outcomes like birth defects or preterm birth. The study uses existing health records from 1996 to 2022 and does not involve any new treatments or direct contact with participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, MS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
Multiple Locations, Finland
-
Many locations
Multiple Locations, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame stubborn multiple sclerosis?
- Could a gentle zapping of the brain ease MS fatigue and brain fog?
- Engineered immune cells take aim at autoimmune diseases
- Can an extra shot boost COVID protection in autoimmune patients?
- CAR-T therapy targets autoimmune diseases, but trial never started
- Nurse-Led video calls aim to empower MS patients